Betamethasone Acetate
drugOn this page
Also known as NSC-759196betamethasone-acetate
Summary
Betamethasone Acetate (CHEMBL1200538) is an approved small molecule; indicated across 9 conditions including ulcerative colitis and nephrotic syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 9 conditions
- Chemistry: 434.5 Da · C24H31FO6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200538 |
| Name | Betamethasone Acetate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 443967 |
| ChEBI | CHEBI:31275 |
| Molecular formula | C24H31FO6 |
| Molecular weight | 434.5 |
| InChIKey | AKUJBENLRBOFTD-QZIXMDIESA-N |
SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)F)C
IUPAC name: [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
Also known as: Betamethasone acetate, NSC-759196, BETAMETHASONE ACETATE, betamethasone-acetate
Patent coverage: 1,047 distinct patent families (3,987 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| ulcerative colitis | 4 | MONDO:0005101 | EFO:0000729 |
| nephrotic syndrome | 4 | MONDO:0005377 | EFO:0004255 |
| type III hypersensitivity disease | 4 | MONDO:0007004 | EFO:1001222 |
| anemia | 4 | MONDO:0002280 | MONDO:0002280 |
| dermatitis | 4 | MONDO:0002406 | MONDO:0002406 |
| asthma | 4 | MONDO:0004979 | MONDO:0004979 |
| disease of the tendon | 3 | MONDO:0100010 | EFO:1001434 |
| osteoarthritis | 3 | MONDO:0005178 | MONDO:0005178 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).